Helix Acquisition shareholders approve business combination with MoonLake, name change to MoonLake Immunotherapeutics

MoonLake Immunotherapeutics

Business Combination Agreement with MoonLake Immunotherapeutics AG approved; 11.5M votes for, 549K against.
Name change to "MoonLake Immunotherapeutics" and adoption of amended charter authorized.
Shareholders redeemed 8,080,845 Class A shares at ~$10.00/share for aggregate ~$80.8M cash.
Incentive Plan (MoonLake Immunotherapeutics 2022 Equity Incentive Plan) approved with 12.0M votes for.
Issuance of shares to BVF shareholders and ML Parties approved under Nasdaq listing rules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.